ClinicalTrials.gg
CompletedNCT01123824Updated Dec 15, 2011

Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects

A Phase 1 interventional study of CLOPIDOGREL and placebo in Healthy, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-15.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Primary Objective:

  • Investigate the possible role of the CYP2C19 genotype in Adenosine diphosphate (ADP)-induced platelet aggregation after administration of a standard dose regimen of clopidogrel (300 mg loading dose followed by 75 mg/day for 4 days) in healthy male and female subjects

Secondary Objectives:

  • Assess the pharmacodynamic activity of a higher dose regimen of clopidogrel (600 mg loading dose followed by 150 mg/day for 4 days)
  • Compare the pharmacokinetic profiles of clopidogrel active metabolite between the selected groups of genotyped subjects and the 2 dose regimen
Read the detailed description

The total study duration per subject is 10-12 weeks broken down as follows:

  • Screening: 2 to 40 days before the first dosing
  • Period 1: 7 days including 5 days treatment
  • Washout: At least 14 days after the last dosing
  • Period 2: 7 days including 5 days treatment
  • End of study: 7 to 10 days after the last dosing
02

Conditions studied

  • Healthy

Keywords

  • healthy subjects
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy subject in good health, as determined by a medical history, physical examination including vital signs and clinical laboratory tests:

  • with a body weight between 45 kg and 95 kg if male, between 40 kg and 85 kg if female, and with a (BMI) between 18 and 30 kg/m²
  • classified into one of the 4 groups of metabolizers according to his/her CYP2C19 genotype:

    • Ultrarapid Metabolizers (UMs, CYP2C19*1/*17 and CYP2C19*17/*17)
    • homozygous Extensive Metabolizers (homoEMs, CYP2C19*1/*1)
    • heterozygous Extensive Metabolizers (heteroEMs, CYP2C19*1/*2 and CYP2C19*1/*3)
    • Poor Metabolizers (PMs, CYP2C19*2/*2 and CYP2C19*2/*3)

Exclusion criteria

Exclusion criteria:

  • Evidence of inherited disorder of coagulation/hemostasis functions
  • Subject smoking more than 10 cigarettes or equivalent per day
  • Unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Sequence clopidogrel 300/75 mg - 600/150 mg

    Period 1: * Day 1: clopidogrel, 300 mg loading dose + placebo * Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily Period 2: * Day 1: clopidogrel, 600 mg loading dose * Day 2 to Day 5: clopidogrel, 150 mg, once daily Each intake is at around 8:00 AM fasted for at least 10 hours

    Drug: CLOPIDOGREL · Drug: placebo

  • Experimental
    Sequence clopidogrel 600/150 mg - 300/75 mg

    Period 1: * Day 1: clopidogrel, 600 mg loading dose * Day 2 to Day 5: clopidogrel, 150 mg, once daily Period 2: * Day 1: clopidogrel, 300 mg loading dose + placebo * Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily Each intake is at around 8:00 AM fasted for at least 10 hours

    Drug: CLOPIDOGREL · Drug: placebo

Interventions

  • Pharmaceutical form: tablets Route of administration: oral

    Also known as: SR25990

  • Drugplacebo

    Pharmaceutical form: matching tablets Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Maximum platelet aggregation intensity (MAI) induced by Adenosine diphosphate (ADP) 5 µM after 5 days treatment

    Time frame: Day 5 of each period

Secondary outcomes

  1. Maximum platelet aggregation intensity (MAI) induced by ADP 20 µM after 5 days treatment

    Time frame: Day 5 of each period

  2. Platelet reactivity index -Vasodilator-stimulated phosphoprotein test (PRI-VASP) after 5 days treatment

    Time frame: Day 5 of each period

  3. Clopidogrel active metabolite pharmacokinetic parameters (Cmax, tmax, AUC0-24, AUClast) after 5 days treatment

    Time frame: Up to 24 hours postdose on Day 5 for each period

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
08

References and documents

Publications

  • Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011 Aug;90(2):287-95. doi: 10.1038/clpt.2011.127. Epub 2011 Jun 29. PubMed 21716274 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2010
First posted
May 14, 2010
Start
Apr 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Dec 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01123824
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 14, 2010
Start date
Apr 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Dec 15, 2011

Study contacts

International Clinical Development Study Director
study chair · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion